Natera

The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

The firm said it will offer 4.5 million shares of its common stock at $20 per share. It expects to close its follow-on public offering on July 16.

The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients. 

The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.